Wolfe Research Upgrades Repligen (NASDAQ:RGEN) to Strong-Buy

Repligen (NASDAQ:RGEN) was upgraded by investment analysts at Wolfe Research to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

RGEN has been the topic of several other research reports. UBS Group reduced their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Barclays boosted their price objective on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Roth Mkm started coverage on shares of Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Finally, KeyCorp reissued an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Stock Performance

Shares of Repligen stock opened at $121.13 on Monday. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $100.99 and a twelve month high of $175.77. The stock has a market cap of $6.83 billion, a price-to-earnings ratio of 134.59, a P/E/G ratio of 2.37 and a beta of 1.09. The company’s fifty day moving average is $118.05 and its 200 day moving average is $139.53.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter in the previous year, the firm posted $0.39 earnings per share. Repligen’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Sell-side analysts forecast that Repligen will post 1.99 EPS for the current year.

Hedge Funds Weigh In On Repligen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bayforest Capital Ltd acquired a new position in Repligen in the fourth quarter valued at $32,000. Rachor Investment Advisory Services LLC acquired a new position in Repligen in the fourth quarter valued at $33,000. Measured Wealth Private Client Group LLC acquired a new position in Repligen in the third quarter valued at $29,000. Los Angeles Capital Management LLC acquired a new position in Repligen in the fourth quarter valued at $36,000. Finally, Farther Finance Advisors LLC lifted its holdings in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.